SRNE logo

Sorrento Therapeutics (SRNE) Cash From Investing

Annual CFI

-$28.52 M
-$108.36 M-135.72%

December 31, 2022

Summary

Performance

1-Year Change

-135.72%

3-Year Change

+25.29%

5-Year Change

-72.53%

15-Year Change

-72.53%

SRNE Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

26.66%
SRNE annual cash flow from investing activities is higher than 26.66% of companies in Healthcare sector

High & Low

All-time High

$79.85 M
SRNE annual cash flow from investing activities is currently -135.72% below its historical high of $79.85 million

3-Year Low

-$28.52 M
SRNE annual cash flow from investing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
SRNE previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

May 15, 2025
SRNE next annual earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

Annual CFF

$311.72 M
SRNE annual cash flow from financing activities is $311.72 million

Annual CFO

-$293.86 M
SRNE annual cash flow from operations is -$293.86 million

Annual FCF

-$307.51 M
SRNE annual free cash flow is -$307.51 million

Annual CAPEX

$13.66 M
SRNE annual capital expenditures is $13.66 million

Quarterly CFI

-$140.00 K
-$1.82 M-108.31%

June 30, 2023

Summary

Performance

3-Month Change

-108.31%

1-Year Change

-108.31%

3-Year Change

-108.31%

5-Year Change

-108.31%

SRNE Quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.61%
SRNE quarterly cash flow from investing activities is higher than 41.61% of companies in Healthcare sector

High & Low

All-time High

$78.66 M
SRNE quarterly cash flow from investing activities is currently -100.18% below its historical high of $78.66 million

3-Year Low

-$13.66 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

May 15, 2025
SRNE next earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

Quarterly CFF

$88.81 M
SRNE quarterly cash flow from financing activities is $88.81 million

Quarterly CFO

-$55.66 M
SRNE quarterly cash flow from operations is -$55.66 million

Quarterly FCF

-$55.80 M
SRNE quarterly free cash flow is -$55.80 million

Quarterly CAPEX

$140.00 K
SRNE quarterly capital expenditures is $140.00 thousand

TTM CFI

-$11.58 M
+$1.59 M+12.06%

June 30, 2023

Summary

Performance

3-Month Change

+12.06%

1-Year Change

+12.06%

3-Year Change

+12.06%

5-Year Change

+12.06%

SRNE TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

34.23%
SRNE TTM cash flow from investing activities is higher than 34.23% of companies in Healthcare sector

High & Low

All-time High

$79.85 M
SRNE TTM cash flow from investing activities is currently -114.51% below its historical high of $79.85 million

3-Year Low

-$28.52 M

Earnings dates

Last Quarterly Earnings Report Date

Jun 30, 2023
SRNE previous earnings announcement was published on Jun 30, 2023

Next Quarterly Earnings Report Date

May 15, 2025
SRNE next earnings announcement is scheduled for May 15, 2025

OtherSRNEcash flowmetrics:

TTM CFF

$246.59 M
SRNE TTM cash flow from financing activities is $246.59 million

TTM CFO

-$234.63 M
SRNE TTM cash flow from operations is -$234.63 million

TTM FCF

-$243.21 M
SRNE TTM free cash flow is -$243.21 million

TTM CAPEX

$8.59 M
SRNE TTM capital expenditures is $8.59 million

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

SRNE Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-135.7%-108.3%+12.1%
3 y3 years+25.3%-108.3%+12.1%
5 y5 years-72.5%-108.3%+12.1%

SRNE Cash From Investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-135.7%at low-108.3%+99.0%-114.5%+59.4%
5 y5-year-135.7%+28.6%-100.2%+99.5%-114.5%+72.4%
alltimeall time-135.7%+28.6%-100.2%+99.5%-114.5%+73.1%

Sorrento Therapeutics Cash From Investing History

DateAnnualQuarterlyTTM
Jun 2023
-
-$140.00 K(-108.3%)
-$11.58 M(-12.1%)
Mar 2023
-
$1.68 M(-133.5%)
-$13.17 M(-53.8%)
Dec 2022
-$28.52 M(-135.7%)
-$5.03 M(-37.8%)
-$28.52 M(+11.0%)
Sep 2022
-
-$8.09 M(+368.3%)
-$25.69 M(+110.5%)
Jun 2022
-
-$1.73 M(-87.4%)
-$12.20 M(-117.9%)
Mar 2022
-
-$13.66 M(+519.7%)
$68.19 M(-14.6%)
Dec 2021
$79.85 M(-300.0%)
-$2.21 M(-140.9%)
$79.85 M(+13.0%)
Sep 2021
-
$5.40 M(-93.1%)
$70.64 M(+76.5%)
Jun 2021
-
$78.66 M(-4021.3%)
$40.02 M(-195.5%)
Mar 2021
-
-$2.01 M(-82.4%)
-$41.91 M(+5.0%)
Dec 2020
-$39.92 M(+4.6%)
-$11.41 M(-54.8%)
-$39.92 M(+2.6%)
Sep 2020
-
-$25.23 M(+673.6%)
-$38.90 M(+129.8%)
Jun 2020
-
-$3.26 M(>+9900.0%)
-$16.93 M(+6.3%)
Mar 2020
-
-$21.00 K(-99.8%)
-$15.93 M(-58.3%)
Dec 2019
-$38.17 M(+80.1%)
-$10.39 M(+219.1%)
-$38.17 M(+14.9%)
Sep 2019
-
-$3.26 M(+44.1%)
-$33.23 M(-22.6%)
Jun 2019
-
-$2.26 M(-89.9%)
-$42.91 M(-0.2%)
Mar 2019
-
-$22.27 M(+308.8%)
-$43.02 M(+102.9%)
Dec 2018
-$21.20 M(+28.2%)
-$5.45 M(-57.9%)
-$21.20 M(+22.2%)
Sep 2018
-
-$12.94 M(+447.2%)
-$17.35 M(+92.7%)
Jun 2018
-
-$2.36 M(+427.7%)
-$9.00 M(-29.8%)
Mar 2018
-
-$448.00 K(-72.0%)
-$12.82 M(-22.5%)
Dec 2017
-$16.53 M(-5.3%)
-$1.60 M(-65.1%)
-$16.53 M(-39.5%)
Sep 2017
-
-$4.59 M(-25.7%)
-$27.34 M(+7.0%)
Jun 2017
-
-$6.18 M(+48.5%)
-$25.56 M(+21.6%)
Mar 2017
-
-$4.16 M(-66.5%)
-$21.02 M(+20.4%)
Dec 2016
-$17.45 M(-239.0%)
-$12.41 M(+342.1%)
-$17.45 M(+156.8%)
Sep 2016
-
-$2.81 M(+71.8%)
-$6.79 M(-130.4%)
Jun 2016
-
-$1.63 M(+174.2%)
$22.32 M(+61.8%)
Mar 2016
-
-$596.00 K(-66.1%)
$13.80 M(+9.9%)
Dec 2015
$12.55 M(-218.5%)
-$1.76 M(-106.7%)
$12.55 M(+202.4%)
Sep 2015
-
$26.31 M(-359.0%)
$4.15 M(-118.5%)
Jun 2015
-
-$10.16 M(+451.1%)
-$22.39 M(+81.5%)
Mar 2015
-
-$1.84 M(-81.9%)
-$12.34 M(+16.5%)
Dec 2014
-$10.59 M
-$10.16 M(+4222.6%)
-$10.59 M(+5416.1%)
Sep 2014
-
-$235.00 K(+126.0%)
-$192.00 K(-59.4%)
Jun 2014
-
-$104.00 K(+10.6%)
-$473.00 K(+21.3%)
DateAnnualQuarterlyTTM
Mar 2014
-
-$94.00 K(-139.0%)
-$390.00 K(-22.5%)
Dec 2013
-$503.00 K(-8.2%)
$241.00 K(-146.7%)
-$503.00 K(-37.2%)
Sep 2013
-
-$516.00 K(+2357.1%)
-$800.90 K(+72.1%)
Jun 2013
-
-$21.00 K(-89.9%)
-$465.30 K(-12.1%)
Mar 2013
-
-$207.00 K(+263.8%)
-$529.50 K(-3.4%)
Dec 2012
-$548.00 K(-47.9%)
-$56.90 K(-68.5%)
-$548.00 K(-25.2%)
Sep 2012
-
-$180.40 K(+111.7%)
-$732.20 K(+19.4%)
Jun 2012
-
-$85.20 K(-62.2%)
-$613.30 K(-46.3%)
Mar 2012
-
-$225.50 K(-6.5%)
-$1.14 M(+8.5%)
Dec 2011
-$1.05 M(+2186.3%)
-$241.10 K(+292.0%)
-$1.05 M(+29.7%)
Sep 2011
-
-$61.50 K(-90.0%)
-$810.60 K(+8.2%)
Jun 2011
-
-$613.30 K(+351.6%)
-$749.10 K(+426.8%)
Mar 2011
-
-$135.80 K(<-9900.0%)
-$142.20 K(+209.1%)
Dec 2010
-$46.00 K(-177.6%)
$0.00(0.0%)
-$46.00 K(-20.0%)
Sep 2010
-
$0.00(-100.0%)
-$57.50 K(-532.3%)
Jun 2010
-
-$6400.00(-83.8%)
$13.30 K(-32.5%)
Mar 2010
-
-$39.60 K(+244.3%)
$19.70 K(-66.8%)
Dec 2009
$59.30 K(>+9900.0%)
-$11.50 K(-116.2%)
$59.30 K(-16.2%)
Sep 2009
-
$70.80 K(>+9900.0%)
$70.80 K(>+9900.0%)
Jun 2009
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2008
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2008
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2008
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2008
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2007
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2007
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2007
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2007
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2006
$0.00(0.0%)
-
-
Dec 2005
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2005
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2005
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2005
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2004
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Sep 2004
-
$0.00(0.0%)
$0.00(0.0%)
Jun 2004
-
$0.00(0.0%)
$0.00(0.0%)
Mar 2004
-
$0.00
$0.00
Dec 2003
$0.00
-
-

FAQ

  • What is Sorrento Therapeutics annual cash flow from investing activities?
  • What is the all time high annual CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics annual CFI year-on-year change?
  • What is Sorrento Therapeutics quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics quarterly CFI year-on-year change?
  • What is Sorrento Therapeutics TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Sorrento Therapeutics?
  • What is Sorrento Therapeutics TTM CFI year-on-year change?

What is Sorrento Therapeutics annual cash flow from investing activities?

The current annual CFI of SRNE is -$28.52 M

What is the all time high annual CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high annual cash flow from investing activities is $79.85 M

What is Sorrento Therapeutics annual CFI year-on-year change?

Over the past year, SRNE annual cash flow from investing activities has changed by -$108.36 M (-135.72%)

What is Sorrento Therapeutics quarterly cash flow from investing activities?

The current quarterly CFI of SRNE is -$140.00 K

What is the all time high quarterly CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high quarterly cash flow from investing activities is $78.66 M

What is Sorrento Therapeutics quarterly CFI year-on-year change?

Over the past year, SRNE quarterly cash flow from investing activities has changed by -$1.82 M (-108.31%)

What is Sorrento Therapeutics TTM cash flow from investing activities?

The current TTM CFI of SRNE is -$11.58 M

What is the all time high TTM CFI for Sorrento Therapeutics?

Sorrento Therapeutics all-time high TTM cash flow from investing activities is $79.85 M

What is Sorrento Therapeutics TTM CFI year-on-year change?

Over the past year, SRNE TTM cash flow from investing activities has changed by +$1.59 M (+12.06%)